Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Amgen, Inc.    AMGN

Delayed Quote. Delayed  - 08/25 10:00:00 pm
170.23 USD   -0.36%
08/25 AMGEN : Provides Update On Status Of Parsabiv™ (Etelcalcetide)..
08/25 AMGEN : Provides Update On Status Of Parsabiv(TM) (Etelcalcetide) Ne..
08/24DJAMGEN : FDA Rejects Amgen Hormonal-Imbalance Treatment
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Amgen, Inc. : Amgen : FDA Letter Rejects Expanded Use Of Xgeva For Prostate Cancer

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/27/2012 | 01:22pm CEST

Amgen Inc. (AMGN) received a complete response letter from the U.S. Food and Drug Administration rejecting the expanded use of Xgeva in men with prostate cancer that hasn't spread to the bones.

According to the drug maker, the FDA letter said the agency can't approve the supplemental biologics license application in its present form because the effect on bone metastases-free survival doesn't outweigh the risks, such as osteonecrosis of the jaw, a rare jaw-decay problem.

"We are reviewing the complete response letter and will work with FDA to determine any next steps," said Sean E. Harper, executive vice president of research and development.

Xgeva is currently approved to delay fractures and other bone injuries in patients whose cancer has already spread to the bones. It is also sold under the brand name Prolia as an osteoporosis treatment, but is administered at a lower dose. Xgeva's and Prolia's combined sales in 2011 topped $550 million.

A federal advisory panel in February rejected Amgen's proposal to expand the bone drug's use, saying it was unclear whether the results were clinically meaningful.

Amgen's study of Xgeva in men with prostate cancer that hadn't responded to previous therapies, but hadn't yet spread to the bones showed the drug prolonged median bone metastatis-free survival by 4.2 months.

Shares closed Thursday at $70.79 and were inactive premarket. The stock it up 10% so far this year.

-By Melodie Warner, Dow Jones Newswires; 212-416-2283; melodie.warner@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on AMGEN, INC.
08/25 AMGEN : Provides Update On Status Of Parsabiv™ (Etelcalcetide) New Drug Ap..
08/25 AMGEN : Provides Update On Status Of Parsabiv(TM) (Etelcalcetide) New Drug Appli..
08/24DJAMGEN : FDA Rejects Amgen Hormonal-Imbalance Treatment
08/24DJAMGEN : FDA Rejects Amgen Hormonal-Imbalance Treatment
08/24 CDSCO DENIES AMGEN, INC. (NASDAQ : AMGN) Clinical Trial Waiver For Repatha
08/23 AMGEN : New data adds to understanding of Repatha® (evolocumab) in multiple pati..
08/22 AMGEN : New Data Add To Understanding Of Repatha(R) (Evolocumab) In Multiple Pat..
08/22DJEli Lilly, AstraZeneca Progress With Alzheimer's Drug
08/19 AMGEN INC : Entry into a Material Definitive Agreement, Other Events, Financial ..
08/18 AMGEN : Ayotte – Reilly
More news
Sector news : Bio Therapeutic Drugs
08/23DJDeal for Medivation Is the Latest In a Line of Similar Acquisitions -- WSJ
08/23DJPFIZER : to Acquire Key Drug -- WSJ
08/22DJPfizer's Medivation Deal Latest in Long Line of Similar Acquisitions
08/22DJPFIZER : to Acquire Medivation in Deal Worth $14 Billion -- 4th Update
08/22DJPFIZER : to Acquire Medivation in Deal Worth $14 Billion -- 3rd Update
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
08/25 88 Stock Picks For The Next 30 Years (Or More)
08/25 Shocked! Mylan, Biotechs Swoon After Hillary's Statement
08/25 FDA rejects Amgen's Parsabiv NDA for secondary hyperparathyroidism; shares do..
08/24 Candidate Clinton's harsh comments on high price of Mylan's EpiPen sends biot..
08/22 Why I Didn't Buy Gilead, Apple Or 100 Others, Y'all - Part 3
Advertisement
Financials ($)
Sales 2016 22 777 M
EBIT 2016 11 104 M
Net income 2016 7 460 M
Debt 2016 3 343 M
Yield 2016 2,29%
P/E ratio 2016 17,23
P/E ratio 2017 15,91
EV / Sales 2016 5,74x
EV / Sales 2017 5,30x
Capitalization 127 393 M
More Financials
Chart AMGEN, INC.
Duration : Period :
Amgen, Inc. Technical Analysis Chart | AMGN | US0311621009 | 4-Traders
Full-screen chart
Technical analysis trends AMGEN, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 191 $
Spread / Average Target 12%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Robert A. Bradway Chairman, President & Chief Executive Officer
Esteban Santos Executive Vice President-Operations
David W. Meline Chief Financial Officer & Executive Vice President
Paul R. Eisenberg Chief Medical Officer & Senior VP-Global Medical
Frank J. Biondi Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
AMGEN, INC.4.87%127 850
GILEAD SCIENCES, INC.-20.86%106 233
CELGENE CORPORATION-9.89%85 728
REGENERON PHARMACEUTIC..-26.27%42 671
VERTEX PHARMACEUTICALS..-23.40%23 963
ACTELION LTD17.62%18 399
More Results